{"id":7004,"date":"2025-05-31T13:31:22","date_gmt":"2025-05-31T13:31:22","guid":{"rendered":"https:\/\/www.nordicbioscience.com\/?post_type=biomarker-solution&p=7004"},"modified":"2025-06-13T08:10:14","modified_gmt":"2025-06-13T08:10:14","slug":"gastrointestinal-diseases","status":"publish","type":"biomarker-solution","link":"https:\/\/www.nordicbioscience.com\/biomarker-solution\/gastrointestinal-diseases\/","title":{"rendered":"Gastrointestinal Diseases"},"content":{"rendered":"
\n
\n
\n

Biomarkers for Gastrointestinal Diseases <\/h1>\n

We have a wide range of biomarkers for gastrointestinal diseases, especially biomarkers for ulcerative colitis and biomarkers for Crohn\u2019s disease. On this page, you can also read the rationale behind some of our most popular biomarkers for IBD.<\/p>\n

\n \n Browse gastroenterology biomarkers \n \n <\/svg>\n \n <\/a>\n <\/div>\n <\/article>\n <\/div>\n<\/section>\n\n\n\n\n
\n \n
\n
\n
\n
\n

CPa9-HNE (NordicCPa9-HNE\u2122)\u2014The Serum Calprotectin<\/h2>\n \n\n <\/div>\n
\n

CPa9-HNE\u2122 is the serum calprotectin biomarker that measures true neutrophil activity by detecting a specific calprotectin fragment. Unlike full-length calprotectin, CPa9-HNE is released only during active inflammation, making it a valuable tool for assessing immune response and monitoring treatment effects in conditions like IBD. Supported by an FDA Letter of Support, it has potential for improving clinical trials by enabling non-invasive assessment of disease activity.<\/p>\n <\/div>\n

\n

Publications<\/h3>\n